Clinical trials: Nutrition Disorder
Pre Diabetes, Overweight
A Study to Determine the Safety and Tolerability of a Range of Doses of PeptiControl in Pre-diabetic Individuals
A randomised, double blind, placebo controlled parallel study to examine the effects of a dose range of PeptiControl, a plant-based ingredient, in pre-diabetic males and females.
- Trial name
- NCT06440213
- Testing
- PeptiControl™ (Low - Dose 435 mg/day), PeptiControl™ (Mid - Dose 870 mg/day), PeptiControl™ (High - Dose 2610 mg/day)
- Where
- 4 sites in India
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Nuritas Ltd
COPD (Chronic Obstructive Pulmonary Disease), Obesity Hypoventilation Syndrome (OHS)
Assessment of Breathing Pattern During NIV
COPD and OHS are respiratory conditions that disrupt normal breathing. Positive airway pressure, specifically Non-Invasive Ventilation (NIV), has been shown to improve breathing and reduce symptoms in patients with these…
- Trial name
- NCT06682286
- Testing
- NIV mask A, NIV mask B
- Where
- New Zealand
- Volunteers
- 40 people
- Sponsor
- Fisher and Paykel Healthcare
Obesity, Type 2 Diabetes
Creation of Side-to-Side Compression Anastomosis Using the GT Metabolic Solutions DI Biofragmentable Magnetic Anastomosis System in Mexico
The purpose of this clinical research study is to evaluate the feasibility / performance, safety and initial efficacy of the GT Metabolic Solutions DI Biofragmentable Magnetic Anastomosis System (MAGNET System, DI…
- Trial name
- NCT07085741
- Testing
- MAGNET System, DI Biofragmentable
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- GT Metabolic Solutions, Inc.
Overweight , Obesity
TRPTI Metabolic and GLP-1 Pharmacodynamic Study
The goal of this clinical trial is to assess whether TRPTI™ supplementation affects GLP-1 and related metabolic markers in generally healthy adults who are overweight or obese (BMI 25.0-34.9 kg/m², aged 30 years and older).
- Trial name
- NCT07850466
- Testing
- TRPTI
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- RDC Clinical Pty Ltd
Overweight, Obesity
Effects of Obex in Overweight and Obese Patients
Obesity is an important and growing public health worldwide Obesity is highly related to the development of metabolic syndrome, diabetes, cardiovascular diseases and cancer An extensive body of evidence from efficacy trials has…
- Trial name
- NCT02145442
- Testing
- Obex
- Where
- Cuba
- Volunteers
- 40 people
- Sponsor
- Catalysis SL
Obesity
A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age
Study will evaluate the pharmacokinetics (PK), safety and tolerability of a single 10 mg dose of lorcaserin hydrochloride in obese pediatric subjects 6 to 11 years of age.
- Trial name
- NCT02398669
- Testing
- Lorcaserin hydrochloride
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Eisai Inc.
Obesity & Overweight
Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults
This is a phase 2 randomized, double-blind, placebo-controlled, multi-center study evaluating the efficacy and safety of LUM-201 plus Semaglutide versus Semaglutide plus placebo in obese adults with body mass index between 30 and…
- Trial name
- NCT07754045
- Testing
- LUM-201, Semagludtide
- Volunteers
- 202 people
- Sponsor
- Lumos Pharma
Crohn's Disease(CD)
Partial-enteral Nutrition Protocol for Crohn's Disease
A novel dietary intervention combining a standardized IBD diet (IBD-AID) with supplementation from a pea protein plant-based oral nutrition supplement (ONS) (Kate Farms Peptide 1.5) to improve protein, calorie, and nutrient…
- Trial name
- NCT07113431
- Testing
- IBD-AID diet combined with Kate Farms Peptide 1.5, IBD-AID diet
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Kate Farms Inc
Obesity, Overweight
Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.
- Trial name
- MARITIME-PEN (NCT07871409)
- Testing
- Maridebart cafraglutide, Autoinjector
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- Amgen
Metabolism and Nutrition Disorder, Obesity
Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects
This trial is conducted in the United States of America (USA). The aim of the trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) for single doses of NNC9204-0530 alone…
- Trial name
- NCT02235961
- Testing
- NNC9204-0530, liraglutide
- Where
- United States
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Acidosis
Safety of D-lactate Producing Probiotics
In this study the investigators want to test the safety of D-lactate producing probiotics in babies from birth to 1 month of age.
- Trial name
- NCT01119170
- Testing
- Starter formula, starter formula with D-lactate producing probiotics
- Where
- Greece
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
OSA, Overweight or Obesity
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization.
- Trial name
- ATTAIN-OSA (NCT06649045)
- Testing
- Orforglipron
- Where
- 66 sites in United States, Argentina and 7 more
- Volunteers
- 712 people
- Sponsor
- Eli Lilly and Company
Aneurysmal Subarachnoid Hemorrhage
Efficacy and Safety Study of a Low-carbohydrate Tube Feed in Critically Ill Patients Under Insulin Therapy
The purpose of this study is to determine the efficacy and safety of a diabetes-specific tube feed in comparison to an isocaloric, isonitrogenous standard enteral formula in critically ill patients receiving insulin treatment for…
- Trial name
- NCT02503527
- Testing
- Diben 1.5 kcal HP, Fresubin HP Energy Fibre (1.5 kcal)
- Where
- Austria
- Volunteers
- 28 people
- Sponsor
- Fresenius Kabi
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes.
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- NCT06972472
- Testing
- Orforglipron
- Where
- 80 sites in United States, Argentina and 5 more
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Obesity
Efficacy of Polyglucosamine Long Term Treatment
The polyglucosamine, specification L112, is a medical device and in this clinical trial used for weight reduction in moderately obese participants following a long term treatment lasting 12 months.
- Trial name
- NCT02682277
- Testing
- polygucosamine
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Certmedica International GmbH
Obesity
Obalon Navigation/Touch System Post-Approval Study
Post-approval study for the Obalon Navigation/Touch System (NTS)
- Trial name
- NTS PAS (NCT04095481)
- Testing
- Obalon Navigation/Touch System
- Where
- 2 sites in United States
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Obalon Therapeutics, Inc.
Overweight or Obesity, Type2 Diabetes Mellitus
Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
This study will evaluate safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects on GSBR-1290 in healthy overweight/obese volunteers (HOV) and Type 2 Diabetes Mellitus on Metformin (T2DM) This study…
- Trial name
- NCT05762471
- Testing
- GSBR-1290
- Where
- 4 sites in United States
- Volunteers
- 142 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obesity
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants
The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo after 26 weeks of treatment on the percent change in body weight from baseline and to assess the safety and tolerability, in non-diabetic…
- Trial name
- NCT03486392
- Testing
- JNJ-64565111 Dose Level 1, JNJ-64565111 Dose Level 2, JNJ-64565111 Dose Level 3
- Where
- 51 sites in United States, Belgium and 4 more
- Volunteers
- 474 people
- Sponsor
- Janssen Research & Development, LLC
Obesity, Non-Alcoholic SteatoHepatitis (NASH)
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
This study is open to adults who are at least 18 years old and have presumed or confirmed NASH together with overweight or obesity and a body mass index (BMI) of 30 kg/m² or more, or a BMI of 27 kg/m² and at least one…
- Trial name
- NCT06309992
- Testing
- Survodutide
- Where
- 37 sites in United States, Spain
- Volunteers
- 218 people
- Sponsor
- Boehringer Ingelheim
Osteoarthritis
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee…
- Trial name
- ATTAIN-OA PAIN (NCT07153471)
- Testing
- Orforglipron
- Where
- 88 sites in United States, Canada and 5 more
- Volunteers
- 800 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.